<DOC>
	<DOCNO>NCT00807079</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin topotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose topotecan give together carboplatin see well work treat patient relapse metastatic cervical cancer .</brief_summary>
	<brief_title>Carboplatin Topotecan Treating Patients With Relapsed Metastatic Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose topotecan hydrochloride administer carboplatin patient relapse metastatic cervical cancer . ( Phase I ) - To determine objective response rate patient treat regimen . ( Phase II ) Secondary - To determine dose-limiting toxicity regimen patient . ( Phase I ) - To assess progression-free survival patient treat regimen . ( Phase II ) - To assess overall survival patient treat regimen . ( Phase II ) - To assess tolerability regimen patient . ( Phase II ) OUTLINE : This multicenter , phase I dose-escalation study topotecan hydrochloride follow phase II study . Patients receive oral topotecan hydrochloride day 1 , 8 , 15 carboplatin IV day 1 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Patients complete quality-of-life questionnaire baseline every 3 month thereafter . After completion study therapy , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cervical cancer , include follow cell type : Squamous cell carcinoma Adenocarcinoma Adenosquamous cell carcinoma Metastatic disease first relapse Not curable surgery and/or radiotherapy without chemotherapy At least 1 nonirradiated measurable lesion No CNS metastases PATIENT CHARACTERISTICS : WHO performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Transaminases ≤ 3 time upper limit normal ( ULN ) ( ≤ 5 time ULN presence liver metastasis ) Total bilirubin ≤ 1.5 time ULN Creatinine clearance ≥ 50 mL/min Not pregnant nursing Fertile patient must use effective contraception No cancer within past 5 year except adequately treat basal cell squamous cell carcinoma skin No swallow disorder gastrointestinal disease result inability take oral medication requirement IV alimentation No alter intestinal absorption No peptic ulcer No nephrostomy DoubleJ catheter allow None follow cardiovascular condition within past 6 month : Uncontrolled hypertension Coronary artery disease NYHA class III IV congestive heart failure Ventricular arrhythmia Unstable angina Myocardial infarction No infection serious illness would preclude study treatment No contraindication study treatment No psychological , familial , sociological , geographical condition would preclude followup PRIOR CONCURRENT THERAPY : No prior cytotoxic therapy except chemoradiotherapy pelvic radiotherapy At least 6 month since prior platinumbased chemoradiotherapy No concurrent participation another clinical trial could interfere objective study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>